We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The lead product candidate of the company is AT-001, which is a novel ARI with broad systemic expos... Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The lead product candidate of the company is AT-001, which is a novel ARI with broad systemic exposure and peripheral nerve permeability, developed for the treatment of diabetic cardiomyopathy, or DbCM, a fatal fibrosis of the heart. Show more
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against...
NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against...
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against...
NDA for govorestat accepted and granted Priority Review by FDA for the treatment of Classic Galactosemia; PDUFA target action date of August 28, 2024; MAA under review by EMA with decision...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.2 | 4.43458980044 | 4.51 | 4.88 | 4.39 | 463808 | 4.7137346 | CS |
4 | -0.83 | -14.9819494585 | 5.54 | 5.57 | 4.165 | 716823 | 4.63444525 | CS |
12 | 1.56 | 49.5238095238 | 3.15 | 9.39 | 2.8 | 1834352 | 5.77295388 | CS |
26 | 2.36 | 100.425531915 | 2.35 | 9.39 | 1.79 | 1591653 | 4.36201602 | CS |
52 | 3 | 175.438596491 | 1.71 | 9.39 | 1.18 | 1079158 | 3.73375651 | CS |
156 | -12.64 | -72.8530259366 | 17.35 | 25.59 | 0.4995 | 547683 | 3.57088027 | CS |
260 | -3.33 | -41.4179104478 | 8.04 | 57.39 | 0.4995 | 383524 | 7.36768323 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions